Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.
A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.
The combination of panobinostat, dexamethasone, and subcutaneous (SC) bortezomib shows promising responses in patients with relapsed or relapsed and refractory multiple myeloma (RRMM), according to the phase II PANORAMA 3* study. Furthermore, SC bortezomib may be preferable to the intravenous (IV) option for reducing toxicity.